Greenwich LifeSciences (GLSI) Long-Term Debt Issuances (2021 - 2022)

Greenwich LifeSciences (GLSI) posted Long-Term Debt Issuances of $2.0 million for Q2 2022, down 63.32% on a QoQ basis from $5.5 million in Q1 2022, and up 1585.42% year-over-year from $120000.0 in Q2 2021.

Greenwich LifeSciences (GLSI) Long-Term Debt Issuances (2021 - 2022) Analysis & Trends

Greenwich LifeSciences' Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at $2.0 million for Q2 2022.

  • Quarterly Long-Term Debt Issuances rose 1585.42% year-over-year to $2.0 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $7.0 million (changed N/A YoY) and the FY2021 annual result came in at -$275154.0, down 176.43% from the prior year.
  • Long-Term Debt Issuances was $2.0 million for Q2 2022 at Greenwich LifeSciences, down from $5.5 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $5.5 million in Q1 2022 and bottomed at -$550308.0 in Q4 2021.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Greenwich LifeSciences 178.53 Mn 178.53 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2022 2.02 Mn
Jun 30, 2022 2.02 Mn
Mar 31, 2022 5.51 Mn
Mar 31, 2022 5.51 Mn
Dec 31, 2021 -550,308.00
Dec 31, 2021 -550,308.00
Jun 30, 2021 120,000.00
Jun 30, 2021 120,000.00
Mar 31, 2021 275,154.00
Mar 31, 2021 275,154.00